What is SiSaf?
SiSaf Ltd operates at the intersection of material science and molecular biology, specializing in the development of RNA therapeutics. The company's core value proposition lies in its proprietary Bio-Courier technology, which integrates bioabsorbable silicon with organic materials to optimize the delivery of nucleic acids. This platform is specifically engineered to overcome traditional barriers in drug administration, offering potential breakthroughs for patients suffering from pancreatic cancer, metastatic malignancies, and osteopetrosis.
Headquartered in England, SiSaf maintains state-of-the-art research and manufacturing facilities that enable end-to-end development of its therapeutic candidates. By focusing on high-unmet-need indications, the company has established a robust market position, effectively bridging the gap between laboratory-scale innovation and scalable clinical application.
How much funding has SiSaf raised?
SiSaf has raised a total of $16.7M across 2 funding rounds:
Series A
$3.5M
Series B
$13.2M
Series A (2016): $3.5M with participation from Vickers Venture Partners and Exen Capital
Series B (2020): $13.2M led by Vickers Venture Partners and Future Fund
Key Investors in SiSaf
Vickers Venture Partners
A global venture capital firm specializing in deep tech investments with a significant track record in scaling high-growth companies across international markets.
Future Fund
An Australian sovereign wealth fund established to manage public sector superannuation liabilities and support long-term economic growth.
Exen Capital
An investment firm with a focus on strategic venture capital, private equity, and yield-generating middle-market lending strategies.
What's next for SiSaf?
With the recent capital infusion, SiSaf is poised to accelerate its clinical development programs and expand its manufacturing capabilities. The strategic focus will likely center on advancing its lead candidates through rigorous regulatory pathways while further validating the Bio-Courier platform's versatility across diverse therapeutic areas. As the company scales, it will continue to leverage its deep-tech expertise to forge partnerships that enhance its reach in the global biopharma market.
The firm's ability to attract institutional capital suggests a long-term commitment to transforming the standard of care for complex disorders. Future milestones will likely involve expanded clinical trials and potential licensing agreements, as SiSaf seeks to solidify its role as a leader in the next generation of RNA-based medicine.
